|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||February 01, 2021|
|Effective date (End):||January 31, 2022|
|Field of knowledge:||Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology|
|Principal Investigator:||Claudia Pinto Marques Souza de Oliveira|
|Grantee:||Pedro Fukui Umeta|
|Home Institution:||Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil|
Non-alcoholic fatty liver disease (NAFLD) is a worldwide epidemic and may progress, in the long run, to steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC). There is an immediate need to better understand its pathogenesis, as well as to develop an effective therapy to prevent its evolution to the most severe forms. Based on these observations, we aim to evaluate the effects of a multiquinase inhibitor, sorafenib, on experimental liver carcinogenesis secondary to NAFLD. For this, we will evaluate the protein expression for glutamine synthetase, HEP-PAR-1, survivin, VEGF, VEGFR-1 and VEGFR-2, p53, EGFR and beta-catenin in an experimental model of NAFLD and HCC with and without the use of sorafenib.